Tag Archive | "Scientific Publication"

First study results featured in USA Today, Time, & Medscape

The first major study results from PPMI were recently highlighted in several national news outlets. USA Today, Time, and Medscape featured the study, which was published in the journal JAMA Neurology. Researchers sought to evaluate the baseline characteristics and relationship to clinical features of CSF biomarkers in de novo PD subjects and healthy controls enrolled in PPMI.

Continue reading...

First major PPMI results published in JAMA Neurology

The first major study results were published in the journal JAMA Neurology. Researchers sought to evaluate the baseline characteristics and relationship to clinical features of CSF biomarkers in de novo PD subjects and healthy controls enrolled in PPMI. They found that measures of CSF A?1-42, T-tau, P-tau181, and ?-synuclein have prognostic and diagnostic potential in early-stage PD. Further investigations using the entire PPMI cohort will test the predictive performance of CSF biomarkers for PD progression.

Continue reading...

New publication on CSF biomarkers features PPMI data

Les Shaw and John Q. Trojanowski, Co-PI's of the PPMI Bioanalytics Core, are co-authors on a paper published in Acta Neuropathologica that used both PPMI and ADNI data to look at correlations between CSF biomarkers and cognitive impairment.

Continue reading...

Researchers Publish First Paper Using PPMI Data

Daniel Weintraub, MD, and a team at the University of Pennsylvania publish the first paper using PPMI data demonstrating that Parkinson's itself does not confer a higher risk for ICDs, supporting other research that suggests the high prevalence of ICDs in people with PD is related to Parkinson's medications, and not the disease itself.

Continue reading...

Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study (Neurology)

Dr. Daniel Weintraub analyzes the QUIP data from the PPMI database to assess frequencies of impulse disorders in PD patients and comparing this to control participants. Through his analysis using multivariable models, a diagnosis of PD was not associated with symptoms of any impulse control or related behavior (p ? 0.10 in all cases).

Continue reading...

Dr. Norbert Schuff to present preliminary findings on DTI in PPMI at the 2012 AAN Annual Meeting

Dr. Norbert Schuff will be presenting "Distribution of Diminished Brain Microstructure in Parkinson's Disease: A Diffusion Tensor Imaging Study of the Parkinson's Progression Marker Initiative" during the Pathophysiology and Diagnosis of Parkinson's Disease Scientific Session at the AAN Annual Meeting on Wednesday, April 25.

Continue reading...

PPMI published in Progress in Neurobiology

The Parkinson's Progression Markers Initiative Study group has published a paper in Progress in Neurobiology. The paper provides an overview of the study development, innovative design, and study objectives.

Continue reading...

PPMI study commissions first interlaboratory study of alpha-synuclein immunoassay performance

The Bioanalytics core of PPMI recently organized the first interlaboratory study to assess the within-center precision of immunoassays for a-SYN measurement in CSF. The long term goal of these studies to optimize and validate an a-SYN biomarker assay for use in the PPMI and other research biomarker studies of PD and PDD as well as to set the stage for wider clinical use of these diagnostic assays beyond specialized research centers. The initial results of these detailed statistical analyses were discussed amongst the participants and will be discussed at the MJFF-hosted PD Therapeutics meeting.

Continue reading...

Biomarkers for Parkinson’s disease (Science Translational Medicine)

This publication, authored by MJFF CEO Todd Sherer, makes a case for why biomarkers are important tools to research, the challenges involved, and what it will take to develop them.

Continue reading...

?-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson’s Disease Patients

This recent publication suggests that there may be elevated levels of antibodies acting against alpha-synuclein in the serum of PD patients when compared to controls. This may mean that an immune response to synuclein is occurring. The preliminary data from this paper provides an excellent example of the kind of research that could utilize the PPMI biorepository for further biomarker verification study.

Continue reading...